Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Alemtuzumab is an injectable drug used for the treatment of B-cell chronic
lymphocytic leukemia (B-CLL). People with CLL have too many of a type of white
blood cell called lymphocytes in the blood and bone marrow. Alemtuzumab is an
antibody that targets a protein called CD52 that is found on the surface of the
lymphocytes. Alemtuzumab attaches to lymphocytes and then activates the immune
system to help kill the lymphocytes.